Thanks Zuess! Even with some delays, there are plenty of near term catalysts that IMO when we look back will seem crazy that this stock could've been purchased at these prices....but I guess time will tell a better story. I have been doing somewhat the opposite of you as I have been somewhat consolidating into CYDY outside my 401k.

I think it was Trding that mentioned he would take RP over any other CMO in the CCR5/oncology sector.....and I concur 100%. IMO RP is the real deal and he alone should bring some valuation to the company that we haven't seen (other than the initial spike when the deal was announced, but has since faded). Other than the TNBC delay (likely not entirely his fault, but largely either the FDA or test centers) every action from him to me clearly displays his confidence in leronlimab working in cancer metastasis (long research history, CCR5 patents, subject matter expert on other CCR5 inhibitors in cancer, 'all-in' in leronlimab/CYDY, preclinical results, etc. I don't think anyone would risk their life's work or as much as he has if he was not 100% confident in this being successful in cancer. So if I am crazy in being confident in the future of CYDY, then so is RP.....and RP sounds extremely sane and I haven't referred to a shrink yet!